Cargando…

The role of combination therapy with corticosteroids and long-acting β(2)-agonists in the prevention of exacerbations in COPD

Acute exacerbations of COPD can complicate the course of the disease in patients with severe airway obstruction. Reduction of exacerbations is an important clinical outcome in evaluating new therapies in COPD. Combination therapies with long-acting β-agonists and inhaled corticosteroids have now bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cazzola, Mario, Hanania, Nicola A
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2006
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707808/ https://www.ncbi.nlm.nih.gov/pubmed/18044091

Ejemplares similares

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019)

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis
por: Oba, Yuji, et al.
Publicado: (2014)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
por: Yang, Hsi-Hsing, et al.
Publicado: (2017)

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
por: Pavord, Ian D, et al.
Publicado: (2016)

Revisiting the Use of Antibiotics to Prevent COPD Exacerbation: Is Doxycycline the Answer?
por: Adrish, Muhammad, et al.
Publicado: (2023)

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β(2)-Agonist Therapy: An Integrated Post Hoc Analysis
por: Naya, Ian P., et al.
Publicado: (2018)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
por: Scichilone, Nicola, et al.
Publicado: (2014)

The benefits of combined treatment with corticosteroids and long-acting beta agonists
por: Singh, Dave
Publicado: (2006)

Long-acting muscarinic antagonists vs. long-acting β (2) agonists in COPD exacerbations: a systematic review and meta-analysis
por: Maia, Israel Silva, et al.
Publicado: (2017)

Transcriptome analysis in patients with asthma after inhaled combination therapy with long-acting β2-agonists and corticosteroids
por: Liang, Ya-Ru, et al.
Publicado: (2022)

Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
por: Rossi, Andrea, et al.
Publicado: (2008)

Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
por: Wang, Cheng-Yi, et al.
Publicado: (2019)

The safety of long-acting β(2)-agonists in the treatment of stable chronic obstructive pulmonary disease
por: Decramer, Marc L, et al.
Publicado: (2013)

Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long‐Acting β (2)‐Agonists and Inhaled Corticosteroids: The OUTPUL Study
por: Ferroni, Eliana, et al.
Publicado: (2016)

Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities
por: Matera, Maria Gabriella, et al.
Publicado: (2023)

Novel Anti-Inflammatory Approaches to COPD
por: Cazzola, Mario, et al.
Publicado: (2023)

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
por: Huang, Tsan-Ming, et al.
Publicado: (2020)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
por: Beier, Jutta, et al.
Publicado: (2011)

High use of short-acting β(2)-agonists in COPD is associated with an increased risk of exacerbations and mortality
por: Janson, Christer, et al.
Publicado: (2023)

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
por: Sion, Katya Y. J., et al.
Publicado: (2017)

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β(2) agonist: observational matched cohort study (PATHOS)
por: Janson, Christer, et al.
Publicado: (2013)

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)
Publicado: (2013)

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β(2)-agonist fixed-dose combination: RE(2)SPOND rationale and study design
por: Rennard, Stephen I, et al.
Publicado: (2016)

Physicians’ attitudes towards combination therapy with inhaled corticosteroids and long-acting β(2)-agonists: an observational study in UK specialist care
por: Thomas, Mike, et al.
Publicado: (2011)

Combined inhaled corticosteroid and long-acting β2-adrenergic agonist therapy for noncystic fibrosis bronchiectasis with airflow limitation: An observational study
por: Wei, Ping, et al.
Publicado: (2016)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
por: Matera, Maria Gabriella, et al.
Publicado: (2015)

A smarter way to manage asthma with a combination of a long-acting β(2)-agonist and inhaled corticosteroid
por: Selroos, Olof
Publicado: (2007)

Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years
por: McGeachie, Michael J., et al.
Publicado: (2020)

An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone
por: Alakeel, Yousif S., et al.
Publicado: (2022)

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Nebulized corticosteroids in the management of acute exacerbation of COPD
por: Gaude, G. S., et al.
Publicado: (2010)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma–COPD overlap syndrome
por: Lee, Suh-Young, et al.
Publicado: (2016)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Relationship Between Blood Eosinophils and Systemic Corticosteroid Therapy in COPD Exacerbation
por: Gong, Yaya, et al.
Publicado: (2022)

Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality
por: Salpeter, Shelley R
Publicado: (2007)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
por: Liao, Pei-An, et al.
Publicado: (2023)

Combined inhaled corticosteroid and long-acting β2-adrenergic agonist therapy for noncystic fibrosis bronchiectasis with airflow limitation: An observational study: Notice of Retraction
Publicado: (2017)

Estimating Inhaled Corticosteroid Exposure from Short-Acting β(2)-Agonist–Inhaled Corticosteroid Rescue
por: Lugogo, Njira, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_evrap6j674m083mt08bancl61f